Creating Value for a Healthy Society / Creating Innovation

There are currently over 57 million people worldwide who live with dementia, and the number of dementia patients is expected to reach approximately 140 million by 2050 as life expectancy increases globally.¹ Alzheimerʼs disease, which accounts for 60% to 70% of all dementia cases, is thought to be triggered by the accumulation of aggregates of a protein called amyloid β (Aβ) in the brain before cognitive impairment appears. Therefore, for therapies targeting Aβ, early diagnosis and intervention are considered to enhance effectiveness. However, brain imaging examinations (PET scans) and cerebrospinal fluid examinations currently used to assess Aβ accumulation in the brain are only available at a limited number of institutions, and their high costs and invasiveness place a significant burden on patients.
Sysmex has been advancing the development of technologies to assess Aβ accumulation in the brain more simply and rapidly in order to help resolve issues in diagnosing Alzheimerʼs disease. In February 2016, Sysmex and Eisai Co., Ltd. entered into a comprehensive, non-exclusive collaboration agreement for the creation of new diagnostic reagents in the field of dementia. Through the exchange of each otherʼs technologies and knowledge, Sysmex has been engaged in the development of next-generation diagnostic reagents that will enable the early diagnosis of dementia, the selection of treatments, and the monitoring of therapeutic effects.
In 2023, Sysmex launched an assay kit in Japan that assists in assessing Aβ accumulation in the brain by measuring Aβ levels in the blood using its automated immunoassay system. Enabling simple and rapid testing, this reagent is expected to reduce physical, emotional, and financial burdens on patients with a suspected Aβ accumulation in the brain while contributing to early diagnosis and early determination of optimal treatment for patients.
As a further initiative, we are promoting the development of a multi-biomarker panel to identify pathological changes at each stage, from pre-onset to cognitive dysfunction, in Alzheimerʼs disease, as well as to differentiate between various types of dementia, including Alzheimerʼs disease. In 2025, we also obtained manufacturing and marketing approval for an assay kit assessing the risk of adverse reactions associated with Alzheimer’s disease drugs. Furthermore, in April 2026, we launched a research-use reagent in Europe for measuring p-Tau217,² an Alzheimer’s disease-related biomarker.³
Going forward, we will continue to create innovative diagnostic technologies for the prevention and treatment of dementia, aiming to contribute to improving the quality of life (QOL) of patients and their families.

In recent years, there has been a growing demand to resolve social challenges in healthcare. These challenges include reducing physical burdens on patients, improving their quality of life (QOL), detecting lesions at an early stage, creating an environment in which healthcare professionals can concentrate on treatment with a sense of security, and ensuring the equalization of healthcare—correcting regional health disparities so that high-quality medical care is accessible anywhere. Robotic-assisted surgery systems are utilized in laparoscopic surgery, which is performed to reduce the physical burden on patients, assisting healthcare professionals in performing more precise procedures. The market size² of the robotic-assisted surgery system industry is expected to expand at a compound annual growth rate (CAGR) of 13%, reaching approximately 2 trillion yen on a global basis by 2030.
Sysmex began the full-scale introduction of robotic-assisted surgery systems to the Japanese market in 2021. In Japan, procedures performed using the system are currently covered by national health insurance in the fields of urology, gastrointestinal surgery, gynecology, and respiratory surgery, and the cumulative number of procedures performed using the system reached 20,000 as of July 2026. This robotic-assisted surgery system was developed with the aim of contributing to the advancement of medicine through features such as operating arms that move smoothly like human arms and high-definition images that vividly display even the smallest details with a full definition 3D system. In the future, Sysmex aims to contribute to improving skills and knowledge of healthcare professionals by using AI to learn surgeons’ advanced techniques, enabling feedback on surgical procedures, intraoperative navigation assistance, as well as remote instruction and training.
In 2023, a demonstration of remote surgery using the robotic-assisted surgery system was successfully conducted between Singapore and Japan, followed by another successful trial between France and Japan in 2025. These achievements are expected to lead to social implementation in the near future, contributing to improved global access to healthcare. Furthermore, in 2026, we obtained marketing approval in Vietnam and European Conformity (CE) marking under the EU Medical Device Regulation (MDR). This certification enables commercial sales in the European region, further accelerating efforts to enhance healthcare access worldwide.

By integrating the technologies and expertise cultivated in testing and diagnostics with robotic-assisted surgery systems, Sysmex will continue to advance with its surgical intelligence initiatives and promote digital transformation (DX) to ensure a better healthcare journey for each patient, from preoperative testing through surgery and postoperative testing and treatment.

If antimicrobials used to treat infectious diseases are inappropriately used, bacteria in the body may not be fully eliminated sufficiently, allowing the surviving bacteria to become drug-resistant bacteria.¹ As these drug-resistant bacteria proliferate, antimicrobials become less effective, making it difficult to treat infections that would otherwise be mild and treatable. According to an estimate published in 2014, if countermeasures against antimicrobial resistance (AMR) are not taken, the annual number of deaths due to AMR is expected to reach 10 million by 2050.² This high figure is estimated to surpass the number of deaths from cancer, and AMR has therefore been recognized by the World Health Organization (WHO) and various other organizations as a social challenge that must be addressed worldwide.
As a company involved in healthcare, Sysmex is working to establish new testing technologies and develop products to help resolve this challenge. In June 2023, we launched a rapid antibiotic susceptibility testing system in Europe that uses urine samples from patients suspected of having urinary tract infections³ to detect the presence or absence of bacteria and assess the effectiveness of antimicrobials. While conventional antibiotic susceptibility testing takes several days, Sysmex’s proprietary microfluidic technology⁴ enables rapid results in as little as 30 minutes from the start of measurement. This supports the appropriate prescription of antimicrobials at the initial consultation in primary care settings such as clinics. In 2024, the system won the Longitude Prize on AMR, the UKʼs most prominent scientific prize. The prize recognizes and supports the development team that has made the most significant contribution to combating AMR through the development of an affordable, rapid, accurate, and easy-to-use POCT⁵ system that is necessary for appropriate antimicrobial prescribing in medical settings. Since the prizeʼs launch in November 2014, applications have been submitted by more than 250 development teams worldwide.
Furthermore, Sysmex Europe participates in the AMR Industry Alliance, an international industry association comprising pharmaceutical, diagnostic, biotechnology, and other companies, with the aim of promoting measures against AMR. Through international knowledge sharing and awareness-raising activities, Sysmex is committed to promoting the appropriate use of antimicrobials.

Sysmex will continue to contribute to tackling the global threat of AMR by developing and delivering innovative testing and diagnostic technologies.